Select publications

Bianco AR. Targeting c-erbB2 and other receptors of the c-erbB family: Rationale and clinical applications. J Chemother 2004;16(Suppl 4):52-4. Abstract

De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;(16 Suppl 4):iv7-iv13. Abstract

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687-717. Abstract

Emens LA. Trastuzumab: Targeted therapy for the management of HER-2/neuoverexpressing metastatic breast cancer. Am J Ther 2005;12(3):243-53. Abstract

Fisher B et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684-90. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Jakesz R et al; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366(9484):455- 62. Abstract

Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: Update on preclinical studies. Semin Oncol 2003;30(5 Suppl 16):49-53. Abstract

Kudachadkar R, O’Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005;55(3):145-63. Abstract

Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005;41(12):1678-89. Abstract

Olivotto IA et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23(12):2716-25. Abstract

Perez EA et al. NCCTG N9831: May 2005 update. Presentation. ASCO 2005. Abstract 556

Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22(18):3700-4. Abstract

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available

Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Ragaz J et al. Adverse impact of lymphangitic and vascular invasion in early breast cancer: Results from the British Columbia breast cancer outcomes unit. Breast Cancer Res Treat 2002;76(42 Suppl 1);Abstract 119.

Ravdin PM. A computer program to assist in making breast cancer adjuvant therapy decisions. Semin Oncol 1996;23(1 Suppl 2):43-50. Abstract

Ravdin PM et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-91. Abstract

Ravdin PM et al. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 1998;16(2):515-21. Abstract

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2- positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Seidman A et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):1215-21. Abstract

Suter TM et al. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004;13(3):173-83. Abstract

Thürlimann B. BIG1-98: A prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast 2005a;14(Suppl 1):3;S4.

Thürlimann B et al. BIG1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presentation. ASCO 2005;Abstract 511.

Willems A et al. Antibody therapy for breast cancer. Anticancer Res 2005;25(3A):1483-9. Abstract

Winer EP et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2005;23(3):619- 29. Abstract